Postanalytical external quality assessment of warfarin monitoring in primary healthcare

Clinical Chemistry

Volumn 52, Issue 10, 2006, Pages 1871-1878

  Kristoffersen, Ann Helen ^a   Thue, Geir ^b   Sandberg, Sverre ^a,b  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

WARFARIN;

ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; DRUG MONITORING; GENERAL PRACTITIONER; HEART VALVE PROSTHESIS; HUMAN; INTERNATIONAL NORMALIZED RATIO; LUNG EMBOLISM; NORWAY; PRIMARY HEALTH CARE; PROFESSIONAL KNOWLEDGE; QUALITY CONTROL; QUESTIONNAIRE; TREATMENT INDICATION;

ADMINISTRATION, ORAL; AGED; ANTICOAGULANTS; DRUG MONITORING; FAMILY PRACTICE; FEMALE; HEART VALVE DISEASES; HEART VALVE PROSTHESIS; HUMANS; INTERNATIONAL NORMALIZED RATIO; KNOWLEDGE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PHYSICIANS, FAMILY; PRIMARY HEALTH CARE; PULMONARY EMBOLISM; QUALITY CONTROL; QUESTIONNAIRES; WARFARIN;

EID: 33749141470     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2006.071027     Document Type: Article

References (37)

1. Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(Suppl 3):204-33.
2. Levine MN, Raskob G, Beyth RJ, Kearon C, Schulman S. Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(Suppl 3):287-310.
3. Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, D'Angelo A, et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 1996;348:423-8.
4. Kearon C, Ginsberg JS, Kovacs MJ, Anderson DR, Wells P, Julian JA, et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J. Med 2003;349:631-9.
5. Hirsh J, Dalen JE, Anderson DR, Poller L, Bussey H, Ansell J, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 1998;114(Suppl 5):445-69.
6. Reynolds MW, Fahrbach K, Hauch O, Wygant G, Estok R, Cella C, et al. Warfarin anticoagulation and outcomes in patients with atrial fibrillation: a systematic review and metaanalysis. Chest 2004; 126:1938-45.
7. Skeie S, Perich C, Ricos C, Araczki A, Horvath AR, Oosterhuis WP, et al. Postanalytical external quality assessment of blood glucose and hemoglobin A1c: an international survey. Clin Chem 2005; 51:1145-53.
8. Skeie S, Thue G, Sandberg S. Use and interpretation of HbA1c testing in general practice. Implications for quality of care. Scand J Clin Lab Invest 2000;60:349-56.
9. Fraser CG, Harris EK. Generation and application of data on biological variation in clinical chemistry. Crit Rev Clin Lab Sci 1989;27:409-37.
10. Lassen JF, Brandslund I, Antonsen S. International normalized ratio for prothrombin times in patients taking oral anticoagulants: critical difference and probability of significant change in consecutive measurements. Clin Chem 1995;41:444-7.
11. Sandberg S, Thue G. Quality specifications derived from objective analyses based upon clinical needs. Scand J Clin Lab Invest 1999;59:531-4.
12. Fraser CG, Hyltoft PP, Larsen ML. Setting analytical goals for random analytical error in specific clinical monitoring situations. Clin Chem 1990;36:1625-8.
13. Introcaso G, Gesu G. Significance of consecutive international normalized ratio (INR) outcomes using statistical control rules in long-term anticoagulated patients. Optimization of laboratory monitoring and interpretation of borderline measurements. Clin Chem Lab Med 2004;42:294-9.
14. The Norwegian medical association. Statistics and research on physicians in Norway in English, http://www.legeforeningen.no (accessed the January 16, 2006).
15. Peterson CE, Kwaan HC. Current concepts of warfarin therapy. Arch Intern Med 1986;146:581-4.
16. Reikvam A, Sandset PM. Guidelines for Warfarin Treatment in Clinical Practice, 4th ed. Oslo, Norway: The Norwegian Medical Association 2005:13, 16-17, 23.
17. Pell JP, McIver B, Stuart P, Malone DN, Alcock J. Comparison of anticoagulant control among patients attending general practice and a hospital anticoagulant clinic. Br J Gen Pract 1993;43:152-4.
18. Horstkotte D, Piper C, Wiemer M. Optimal frequency of patient monitoring and intensity of oral anticoagulation therapy in valvular heart disease. J Thromb Thrombolysis 1998;5:19-24.
19. Baglin TP, Keeling DM, Watson HG. Guidelines on oral anticoagulation (warfarin): third edition-2005 update. Br J Haematol 2006;132:277-85.
20. Cannegieter SC, Rosendaal FR, Wintzen AR, van der Meer FJ, Vandenbroucke JP, Briet E. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 1995;333:11-7.
21. Salem DN, Stein PD, Al Ahmad A, Bussey HI, Horstkotte D, Miller N, et al. Antithrombotic therapy in valvular heart disease-native and prosthetic: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(Suppl 3):457-82.
22. Stein PD, Alpert JS, Bussey HI, Dalen JE, Turpie AG. Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Chest 2001;119(Suppl 1):220-7.
23. Vink R, Kraaijenhagen RA, Hutten BA, van den Brink RB, de Mol BA, Buller HR, et al. The optimal intensity of vitamin K antagonists in patients with mechanical heart valves: a meta-analysis. J Am Coll Cardiol 2003;42:2042-8.
24. Magid E, Hyltoft PP, Christensen M. A note on the theory of reference changes. Scand J Clin Lab Invest 1992;52:95-101.
25. Reports on instrument trials. http://www.uib.no/isf/noklus/skup/ (accessed May 24, 2006).
26. Taborski U, Braun SL, Voller H. Analytical performance of the new coagulation monitoring system INRatio for the determination of INR compared with the coagulation monitor CoaguChek S and an established laboratory method. J Thromb Thrombolysis 2004;18:103-7.
27. Banet GA, Waterman AD, Milligan PE, Gatchel SK, Gage BF. Warfarin dose reduction vs watchful waiting for mild elevations in the international normalized ratio. Chest 2003;123:499-503.
28. Brosstad F. Arterial and Venous Thromboembolism. Prophylaxis and Treatment, 3rd ed. Department of Medicine, Rikshospitalet, Oslo, Norway: Lobo Media AS 2005:78.
29. Makris M, Watson HG. The management of coumarin-induced over-anticoagulation Annotation. Br J Haematol 2001;114:271-80.
30. Baker RI, Coughlin PB, Gallus AS, Harper PL, Salem HH, Wood EM. Warfarin reversal: consensus guidelines, on behalf of the Australasian Society of Thrombosis and Haemostasis. Med J Aust 2004;181:492-7.
31. Hylek EM, Regan S, Go AS, Hughes RA, Singer DE, Skates SJ. Clinical predictors of prolonged delay in return of the international normalized ratio to within the therapeutic range after excessive anticoagulation with warfarin. Ann Intern Med 2001; 135:393-400.
32. Hylek EM, Chang YC, Skates SJ, Hughes RA, Singer DE. Prospective study of the outcomes of ambulatory patients with excessive warfarin anticoagulation. Arch Intern Med 2000;160:1612-7.
33. Fihn SD, Callahan CM, Martin DC, McDonell MB, Henikoff JG, White RH. The risk for and severity of bleeding complications in elderly patients treated with warfarin. The National Consortium of Anticoagulation Clinics. Ann Intern Med 1996;124:970-9.
34. Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 1994;120:897-902.
35. van der Meer FJ, Rosendaal FR, Vandenbroucke JP, Briet E. Bleeding complications in oral anticoagulant therapy. An analysis of risk factors. Arch Intern Med 1993;153:1557-62.
36. Chiquette E, Amato MG, Bussey HI. Comparison of an anticoagulation clinic with usual medical care: anticoagulation control, patient outcomes, and health care costs. Arch Intern Med 1998; 158:1641-7.
37. Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med 1998;105:91-9.